Serum free light-chain assay for the detection and monitoring of multiple myeloma and related conditions
- PMID: 23610612
- PMCID: PMC3629763
- DOI: 10.1177/2040620712466863
Serum free light-chain assay for the detection and monitoring of multiple myeloma and related conditions
Abstract
Diagnosis and monitoring of multiple myeloma (MM) and related conditions are usually carried out by means of serum and urine protein electrophoresis and immunofixation. In the early 2000s, an assay aimed at evaluating serum free light chains (sFLCs) was made available and subsequently tested in different plasma cell disorders. Several reports have demonstrated the usefulness of the assay for the diagnosis and monitoring of oligosecretory MM, nonsecretory MM, Bence Jones MM, and amyloid light-chain amyloidosis. Furthermore, a prognostic role for an abnormal sFLC κ/λ ratio has been observed in the case of monoclonal gammopathy of unknown significance, smoldering MM, solitary plasmacytomas, and in newly diagnosed symptomatic MM secreting intact monoclonal immunoglobulins. In conclusion, according to present data, the sFLC assay can be considered reliable for the diagnosis, monitoring, and prognosis of different plasma cell disorders, and recently studies have been carried out to test a possible role of an sFLC evaluation in other B-cell lymphoproliferative malignancies.
Keywords: monoclonal immunoglobulins; myeloma; serum free light chains.
Conflict of interest statement
Similar articles
-
Serum Free Light Chain Analysis for the Diagnosis, Management, and Prognosis of Plasma Cell Dyscrasias: Future Research Needs: Identification of Future Research Needs From Comparative Effectiveness Review No. 73 [Internet].Rockville (MD): Agency for Healthcare Research and Quality (US); 2012 Sep. Report No.: 12-EHC135-EF. Rockville (MD): Agency for Healthcare Research and Quality (US); 2012 Sep. Report No.: 12-EHC135-EF. PMID: 23678513 Free Books & Documents. Review.
-
Serum free light chains in clinical laboratory diagnostics.Clin Chim Acta. 2014 Jan 1;427:15-20. doi: 10.1016/j.cca.2013.08.018. Epub 2013 Aug 30. Clin Chim Acta. 2014. PMID: 23999048 Review.
-
Elimination of the need for urine studies in the screening algorithm for monoclonal gammopathies by using serum immunofixation and free light chain assays.Mayo Clin Proc. 2006 Dec;81(12):1575-8. doi: 10.4065/81.12.1575. Mayo Clin Proc. 2006. PMID: 17165636
-
Quantitation of serum free light chains does not compensate for serum immunofixation only when screening for monoclonal gammopathies.Clin Chem Lab Med. 2009;47(9):1109-15. doi: 10.1515/CCLM.2009.254. Clin Chem Lab Med. 2009. PMID: 19728853
-
Serum Free Light Chain Assay and κ/λ Ratio: Performance in Patients With Monoclonal Gammopathy-High False Negative Rate for κ/λ Ratio.J Clin Med Res. 2017 Jan;9(1):46-57. doi: 10.14740/jocmr2802w. Epub 2016 Nov 24. J Clin Med Res. 2017. PMID: 27924175 Free PMC article.
Cited by
-
Bad players in AL amyloidosis in the current era of treatment.Expert Rev Hematol. 2023 Jan;16(1):33-49. doi: 10.1080/17474086.2023.2166924. Epub 2023 Jan 12. Expert Rev Hematol. 2023. PMID: 36620914 Free PMC article.
-
Free Light Chains κ and λ as New Biomarkers of Selected Diseases.Int J Mol Sci. 2023 May 31;24(11):9531. doi: 10.3390/ijms24119531. Int J Mol Sci. 2023. PMID: 37298479 Free PMC article. Review.
-
Human heat shock protein-specific cytotoxic T lymphocytes display potent antitumour immunity in multiple myeloma.Br J Haematol. 2014 Sep;166(5):690-701. doi: 10.1111/bjh.12943. Epub 2014 May 14. Br J Haematol. 2014. PMID: 24824351 Free PMC article.
-
Prognostic impact of rapid reduction of involved free light chains in multiple myeloma patients under first-line treatment with Bendamustine, Prednisone, and Bortezomib (BPV).J Cancer Res Clin Oncol. 2021 Aug;147(8):2349-2359. doi: 10.1007/s00432-020-03504-3. Epub 2021 Jan 12. J Cancer Res Clin Oncol. 2021. PMID: 33433659 Free PMC article.
-
Serum free light chains reference intervals for the Lebanese population.Clin Chem Lab Med. 2024 Dec 5;63(5):e133-e136. doi: 10.1515/cclm-2024-0923. Print 2025 Apr 28. Clin Chem Lab Med. 2024. PMID: 39629797 No abstract available.
References
-
- Bladè J., Kyle R. (1999) Nonsecretory myeloma, immunoglobulin D myeloma, and plasma cell leukemia. Hematol Oncol Clin N Am 13: 1259–1272 - PubMed
-
- Bradwell A., Carr-Smith H., Mead G., Harvey T., Drayson M. (2003) Serum test for assessment of patients with Bence Jones myeloma. Lancet 361: 489–491 - PubMed
-
- Bradwell A., Carr-Smith H., Mead G., Tang L., Showell P., Drayson M., et al. (2001) Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine. Clin Chem 47: 673–680 - PubMed
-
- Charafeddine K., Jabbour M., Kadi R., Daher R. (2012) Extended use of serum free light chain as a biomarker in lymphoproliferative disorders. Am J Clin Pathol 137: 890–897 - PubMed
-
- Davids M., Murali M., Kuter D. (2010) Serum free light chain analysis. Am J Hematol 85: 787–790 - PubMed
LinkOut - more resources
Full Text Sources